Evaluating Glutamatergic Transmission in Schizophrenia
Overview
Affiliations
Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.
Lipina T, Giang H, Thacker J, Wetsel W, Caron M, Beaulieu J Int J Neuropsychopharmacol. 2024; 27(12).
PMID: 39612588 PMC: 11656026. DOI: 10.1093/ijnp/pyae060.
Marballi K, Gallitano A Front Behav Neurosci. 2018; 12:23.
PMID: 29520222 PMC: 5827560. DOI: 10.3389/fnbeh.2018.00023.
Wible C Front Hum Neurosci. 2012; 6:180.
PMID: 22737114 PMC: 3381447. DOI: 10.3389/fnhum.2012.00180.
Measurement of glycine in gray and white matter in the human brain in vivo by 1H MRS at 7.0 T.
Banerjee A, Ganji S, Hulsey K, Dimitrov I, Maher E, Ghose S Magn Reson Med. 2012; 68(2):325-31.
PMID: 22693073 PMC: 3396723. DOI: 10.1002/mrm.24368.
van den Buuse M Schizophr Bull. 2009; 36(2):246-70.
PMID: 19900963 PMC: 2833124. DOI: 10.1093/schbul/sbp132.